July 28th, 2011
AstraZeneca Sets Premium Price for Ticagrelor
Larry Husten, PHD
AstraZeneca will be charging a premium price for its new antiplatelet drug ticagrelor (Brilinta). Wall Street analyst Timothy Anderson reports that the daily treatment cost for the drug will be $7.24 on a wholesaler acquisition cost (WAC) basis, which is approximately 20% higher than the daily cost of $6.08 for clopidogrel (Plavix) and about 25% higher than the daily cost of $5.78 for prasugrel (Effient). AstraZeneca issued the following statement about the price:
“Brilinta will be priced to reflect the label and its value in treating patients with ACS. AstraZeneca believes Brilinta should be priced at a premium because of its label and the safety and efficacy versus clopidogrel. The cost to an individual patient will differ depending on an individual patient’s health insurance status. As with all of our medicines, we want to help make sure that the people who are prescribed Brilinta have access to it.”
Sorry, there are no polls available at the moment.
One Response to “AstraZeneca Sets Premium Price for Ticagrelor”
NEJM Journal Watch — Recent Cardiology Articles- Strategies and Criteria for the Diagnosis and Management of Myocarditis
- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
Likely yes, in the hospital.